Clinical Trial Update: Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Pertuzumab (brand name Perjeta) in the neoadjuvant treatment of HER2-positive breast cancer has completed, with results assessing effi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Perjeta (pertuzumab)
• Pertuzumab (pertuzumab)

Snippet

Sponsor: Cinnagen | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-07-26